Avsnitt
-
Saknas det avsnitt?
-
Host: Brian P. McDonough, MD, FAAFP
Guest: Adam Ehrlich, MD, MPH
Guest: John D. Betteridge, MD
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Brian McDonough leads an expert panel focusing on preventive care for IBD patients. Joining the expert panel are: Dr. Adam C. Ehrlich, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Co-Medical Director of the Temple Inflammatory Bowel Disease Program, and Dr. John D. Betteridge, Gastroenterologist at Lancaster General Hospital and Regional Gi Medical Center. Drs. Ehrlich and Betteridge discuss the issues surrounding IBD with a focus on preventative care in patients. Discussion points include micronutrient deficiencies, immunosuppression, methods to maintain a well-balanced nutrient-rich diet, and communication strategies between PCPs and GI specialists to improve patient care. -
Host: Robert Frankel, MD
Guest: Neilanjan Nandi, MD, FACP
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Robert Frankel talks with Dr. Neilanjan Nandi, Assistant Professor in the Division of Gastroenterology & Hepatology and Associate Director of the Gastroenterology Fellowship program at Drexel University College of Medicine. Dr. Nandi shares new insights on how to approach sexual and intimacy issues for IBD patients. Discussion points include quality of life measures, methods for maintaining healthy intimate relationships, respecting boundaries, and top health practitioner resources. -
Host: Adam Ehrlich, MD, MPH
Guest: Adam Kaufman, MD
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Adam C. Ehrlich talks with Dr. Adam Kaufman, Gastroenterologist at Main Line Gastroenterology Associates. Dr. Kaufman brings to the forefront the importance of preparing your IBD patient for travel. Discussion points include scheduling a pre-travel counsel visit, medication choices and proper storage procedures, vaccination considerations, blood clot prophylaxis, and travel insurance. -
Host: Philip Stein, MD
Guest: Neilanjan Nandi, MD, FACP
Guest: Susan Peck, MSN, CRNP
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Philip Stein talks with Dr. Neilanjan Nandi and nurse practitioner Susan Peck about their respective experiences with The Crohn’s & Colitis Foundation's Camp Oasis. This camp gives children with IBD the opportunity to meet other kids with the same chronic illness, teaching them how to cope with their disease, manage their own medical needs, try new sports and activities, build confidence and independence, and most importantly, spend quality time just being a kid. -
Host: Philip Stein, MD
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Philip Stein talks with Claire Griffin and Bill Johnson, patients and counselors at CCF's Camp Oasis. Claire and Bill discuss their respective involvements with the camp, why they made the decision to go, how they became their own personal advocates, and what Camp Oasis taught them about adjusting to their disease. -
Host: Brian P. McDonough, MD, FAAFP
Guest: John D. Betteridge, MD
Guest: Philip Stein, MD
Guest: Thomas Judge, M.D.
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Brian McDonough moderates an expert gastroenterology panel exploring some of the top issues in IBD management: the best time for primary care clinicians to refer patients to GI, challenges to making an early diagnosis, and differences between IBD and IBS. Panel participants include: Dr. John Betteridge, Gastroenterologist at Lancaster General Hospital and Regional Gi Medical Center in Lancaster, PA Dr. Tom Judge, Gastroenterologist and Director of the Inflammatory Bowel Disease Center at Cooper University Health Care, and Associate Professor of Medicine at the Cooper Medical School of Rowan University Dr. Philip Stein, Pediatric Gastroenterologist at St. Christopher's Hospital and faculty member in the Department of Pediatrics at Drexel University College of Medicine -
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance. Liefferinckx C1, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D. BACKGROUND: Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure. METHODS: This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay. RESULTS: During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12-19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12-12.09 μg/mL], P = 0.007) and in patients responding to ... -
From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Michael and Ellen Araten, recipients of the Founders Award for the Philadelphia Chapter. The Aratens have been involved with the Foundation for over 20 years and discuss how the organization has assisted Ellen and her family upon her diagnosis. Ellen offers her perspective as a patient and the struggles she has overcome with the support of the organization.
-
From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. Jose Fernando Del Rosario, head of Pediatric Gastroenterology at the Nemours Alfred I. duPont Hospital for Children in Wilmington, DE. Dr. Del Rosario and his department are the recipients of this year’s Gold Medallion Award from the Foundation. He discusses providing a positive experience for the patient and the importance of teaching children how to manage their health while living with a chronic condition, regaining quality of life and the most recent treatments for managing IBD, including nutritional therapy.
-
From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. David Piccoli, Chief of the Division of Gastroenterology, Hepatology and Nutrition, Director of the Biesecker PediatricLiver Center, and a board-certified pediatric gastroenterologist at Children's Hospital of Philadelphia. Dr. Piccoli discusses the RISK study, supported by the Crohn’s & Colitis Foundation, and the challenges patients face with response to treatment. This pediatric study enrolled 1,800 patients at the time of their diagnosis and collected clinical, genetic, treatment and microbiome information to help to determine how the immune system works over time.
-
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. BACKGROUND: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. METHODS: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. RESULTS: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). Infliximab was the most frequently used ...
-
Anti-TNFα Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure Assa A1, Bronsky J, Kolho KL, Zarubova K, de Meij T, Ledder O, Sladek M, van Biervliet S, Strisciuglio C, Shamir R. BACKGROUND: The outcome of patients with Crohn's disease who failed anti-tumor necrosis factor alpha (anti-TNFα) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNFα agent postoperatively. METHODS: Pediatric patients with Crohn's disease who underwent intestinal resection and were treated with anti-TNFα agents postoperatively were assessed retrospectively. Patients were stratified to those with preoperative anti-TNFα pharmacodynamic failure and those with no preoperative anti-TNFα treatment. RESULTS: A total of 53 children were included, 18 with pharmacodynamic failure and 35 controls. Median age at intestinal resection was 14.8 years with 23 (43%) girls. The median time from intestinal resection to anti-TNFα initiation was 8 months (interquartile range 4-14 months). At the time of postoperative anti-TNFα initiation, there were no differences in clinical, laboratory, and anthropometric measures between groups. Similar proportions of patients from both groups were in clinical remission on anti-TNFα treatment after 12 months and at the ...
-
Host: Rebecca Kaplan
Guest: Michael E. Kwiatt, MD
When should surgery be considered as a treatment option for patients with Crohn’s or colitis? Host Rebecca Kaplan of the Crohn’s and Colitis Foundation is joined by Dr. Michael Kwiatt, Assistant Professor of Surgery at Cooper University Hospital in New Jersey, to discuss when to consider surgery. Additionally, he will touch on the common surgical complications and differences in surgical approach for patients with respective diseases. -
Host: Rebecca Kaplan
Dealing with inflammatory bowel disease (IBD) on its own is difficult, but managing it with a professional athletic schedule is another task altogether. Dajuan Wagner, a former NBA player, was diagnosed with IBD early in his career. In this episode, he will discuss how he learned to manage his disease, and his advice for physicians treating IBD patients who are also athletes. He is joined by Rebecca Kaplan of the Crohn’s and Colitis Foundation. -
Host: Rebecca Kaplan
Guest: Adam Ehrlich, MD, MPH
As new treatment options become available for IBD patients, it is important to be informed on which treatments will work best for which patient populations. Dr. Adam Ehrlich, Assistant Professor of Medicine at Temple University School of Medicine, joins Rebecca Kaplan to discuss what's coming down the drug pipeline for patients with IBD. He will touch on the recent medication approvals of biologics and biosimilars, as well as how IBD treatments are moving closer to precision medicine. -
Host: Adam Ehrlich, MD, MPH
Guest: Philip Stein, MD
The majority of adolescents with inflammatory bowel disease (IBD) will transition from a pediatric to an adult specialist. This process can be daunting, especially if patients are not ready to take control of their health care. However, with the right communication and preparation, the transition can be smooth for the patient, parent, and physician. Host Dr. Adam Ehrlich joins Dr. Philip Stein, a pediatric gastroenterologist at St. Christopher’s Hospital for Children, to discuss how physicians can best prepare patients to transition and overcome potential difficulties. -
Host: Adam Ehrlich, MD, MPH
Guest: Alison Kaufman, PsyD
Our body responds to stress and anxiety in a variety of ways. For patients with IBD, the body manifests stress into various psychological issues, creating a link between IBD and mental health. Dr. Alison Kaufman, a psychologist at Children’s Hospital of Philadelphia will discuss the common emotional reactions of IBD patients, suggesting ways for physicians to help these patients cope with their chronic disease. She is joined by Dr. Adam Ehrlich of Temple University. -
Host: Rebecca Kaplan
Guest: Neil Nandi, MD
For patients with Crohn's and Colitis diseases, fecal matter transplants could be the therapy they have been waiting for. Dr. Neil Nandi, Director of the Center for Inflammatory Bowel Diseases at Drexel University College of Medicine, will discuss what fecal transplants are, outline the risks and benefits of treatment, and forecast upcoming research. He is joined by Rebecca Kaplan of the Crohn's and Colitis Foundation. - Visa fler
